Posted by Michael Wonder on 15 May 2026
Alloplex Biotherapeutics receives FDA fast track designation for Suplexa in colorectal cancer indication
13 May 2026 - Alloplex Biotherapeutics announces that the US FDA has granted fast track designation to Suplexa for the treatment of patients with colorectal cancer of the MSI-H phenotype.
Suplexa is the first drug candidate to emerge from the proprietary ENLIST immune cell training platform developed at Alloplex.
